摘要
目的:观察绝经后口服替勃龙以及替勃龙加妊马雌酮两种治疗方案对乳腺增生的影响,评估替勃龙及其配伍方案作为激素补充治疗方案的安全性。方法:5 0例绝经后伴有乳腺增生病例,随机分为两组,分别接受替勃龙1.2 5mg每日1次或替勃龙1.2 5mg每日1次加妊马雌酮0 .3mg隔日1次,共服用6个月。并在用药前、用药6个月后行乳腺B超检查,根据治疗前后乳腺B超报告的乳腺导管、纹理及结节的变化情况分别比较两组用药前后的对乳腺增生的影响。结果:替勃龙组治疗后,双侧乳腺导管明显缩小,治疗前后差异有非常显著性(P <0 .0 1)。替勃龙加妊马雌酮组治疗后变化小,治疗前后差异无显著性(P >0 .0 5 )。用药前后替勃龙组左侧乳腺导管治疗变化百分比较替勃龙加妊马雌酮组改变明显(P <0 .0 5 ) ,单纯替勃龙组用药前后乳腺纹理增粗、乳腺结节对比变化有显著性(P <0 .0 5 ) ,而替勃龙加妊马雌酮组变化没有显著性(P >0 .0 5 )。结论:对于有绝经症状并患有乳腺增生的妇女应选择对乳腺影响小又能缓解症状的药物,替勃龙应该是一种较好的选择。
Objectives: This study was aimed at obse rv ing the influence of tibolone or livial plus low dose premarin on breast prolife ration in post menopausal women. Methods:A total of 50 postmenopausal women were enrolled and randomly a llocated into tibolone (1.25mg daily) group or tibolone (1.25mg daily) plus low do se premarin (0.3mg Qod) group. Breast ultrosonography was taken before and after 6 months of treatment, and several parameters of breast ultrosonography were comp ared between the 2 groups. Results:The width of the duc t significantly decreased in tibolone group (P<0.01) while that from livial plus premarin group remained unchanged. The reductive scope of the width of duct in tibolone group was statistically significant(P<0.05). The inciden ce of breast texture thickening or nods decreasedmarkedly in tibolone alone gr oup(P<0.05), while that in the tibolone plus low dose premarin group remaine d unchang. Conclusion s:In sympt omatic postmenopausal women with breast proliferation, a symptom relieving drug with little influence on breast should be applied. Tibolone is a good choice.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2005年第4期231-234,共4页
Journal of Practical Obstetrics and Gynecology
关键词
替勃龙
绝经
激素补充治疗
乳腺
Tibolone
Menopause
Hormone replacement therapy
Breast
